Phase 1 safety study in healthy volunteers of AB680, a small-molecule inhibitor of CD73 and rationale for combination therapy in patients with gastrointestinal malignancies

JOURNAL FOR IMMUNOTHERAPY OF CANCER(2019)

引用 2|浏览18
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要